Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment-Reference-Cited by-同舟云学术

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment

Published:2021-11-22 Issue:1 Volume:62 Page:65-77
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache

Author:

Láinez Miguel J. A.¹,Schoenen Jean²,Stroud Chad³,Bardos Jennifer³,Bangs Mark³,Kemmer Phebe³,Wenzel Richard³,Kuruppu Dulanji K.³,Martinez James Michael³,Oakes Tina M.³

Affiliation:

1. Hospital Clinico Universitario Universidad Católica de Valencia Valencia Spain

2. Department of Neurology Headache Research Unit Citadelle Hospital Liège University Liège Belgium

3. Eli Lilly and Company Indianapolis Indiana USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.14234

Reference29 articles.

1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

2. Increased suicidality in patients with cluster headache

3. Cluster Headache in the United States of America: Demographics, Clinical Characteristics, Triggers, Suicidality, and Personal Burden*

4. Pharmacotherapy for Cluster Headache

5. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities;Current Neurology and Neuroscience Reports;2024-07-17

2. Galcanezumab Add-on in Refractory Cluster Headache;2024-05-23

3. Cluster Headache, SUNCT, and SUNA;CONTINUUM: Lifelong Learning in Neurology;2024-04

4. Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study;Cephalalgia;2024-03

5. Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System;BioDrugs;2024-02-25